Actinium Pharmaceuticals’ (ATNM) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $4.00 target price on the stock.

Separately, Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Actinium Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $1.19 on Tuesday. The firm has a market cap of $37.12 million, a P/E ratio of -0.86 and a beta of 0.10. Actinium Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $10.24. The firm’s 50-day simple moving average is $1.20 and its 200-day simple moving average is $1.46.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. bought a new stake in shares of Actinium Pharmaceuticals during the fourth quarter worth $32,000. Sei Investments Co. acquired a new stake in Actinium Pharmaceuticals in the 4th quarter valued at about $62,000. Barclays PLC raised its stake in shares of Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Actinium Pharmaceuticals by 76.6% during the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $112,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).